// App-Quantinova.ai

526 : Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)

Researchers

Presenter

  • Barbara Eichhorst

Principal Investigators

  • Raymonde Busch

  • Michael Gregor

  • Torben Plesner

  • Marek Trneny

  • Kirsten Fischer

  • Hartmut Dohner

  • Michael Kneba

  • Clemens Wendtner

  • Wolfram Klapper

  • Karl-Anton Kreuzer

  • Elisabeth Lange

  • Stephan Stilgenbauer

  • Sebastian Bottcher

  • Michael Hallek

  • Hubert Koppler

  • Michael G Kiehl

  • Martin Sokler

  • Rudolf Schlag

  • Ursula Vehling-Kaiser

  • Georg R.A. Kochling

  • Christoph Ploger

Medical Centers

  • Abteilung Innere Medizin II, Universitatsklinikum Tubingen, Tubingen, Germany

  • Department of Hematology and Oncology, Evangelisches Krankenhaus Hamm, Hamm, Germany

  • Mannheimer Onkologie Praxis, Mannheim, Mannheim, Germany

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Institute for Medical Statistics and Epidemiology, Technische Universitaet Muenchen, Munich, Germany

  • Department of Internal Medicine, Frankfurt (Oder) General hospital, Frankfurt/Oder, Germany

  • Campus Kiel, nd Dept. of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany

  • Onkolog. Schwerpunktpraxis Dr. Kochling, Villingen-Schwenningen, 78050 VS-Villingen, Germany

  • Department of Dermatology, Charles University, Prague, Czech Republic

  • Hematopathology Section, Christian-Albrechts-University Kiel, Kiel, Germany

  • Hematology Division, Kantonsspital Luzern, Luzern, Switzerland

  • Praxisklinik fuer Haematologie und Onkologie, Koblenz, Germany

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Department of Internal Medicine, Vejle Hospital, Vejle, Denmark

  • Day Clinic Hematology Oncology Palliative Care, Landshut, Germany

  • Lung Cancer Group Cologne, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital Cologne, Cologne, Germany

  • Hematology and Oncology Practice, Wurzburg, Germany

  • Department of Medicine, University Medical Center Schleswig-Holstein, Kiel, Germany

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Department I of Internal Medicine, Klinikum Schwabing, Munich, Germany

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

Locations

  • Germany

  • Czech Republic

  • Denmark

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Chronic Lymphocytic Leukemia

  • Neutropenia

Biomarkers

  • Circulating tumor cells

  • Creatinine

  • Immunoglobulin heavy-chain variable region gene

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Bendamustine

  • fludarabine tablet

  • Rituximab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved